# A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

> **NCT01115803** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 29 (actual)

## Conditions studied

- Metastases, Neoplasm
- Carcinoma, Non-small Cell Lung
- Renal Cell Carcinoma
- Neuroendocrine Tumors

## Interventions

- **DRUG:** LY2584702
- **DRUG:** Erlotinib
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01115803
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Primary objective has been met; safety and pharmacokinetics have been characterized.
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01115803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01115803, "A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01115803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*